We anticipate that the safety problems observed for glitazones in patients with ischemic heart disease [19] may contribute to a more rapid introduction of the DPP-IV inhibitors for add-on therapy in patients with type 2 diabetes not controlled on traditional sulphonyl ureas and metformin. Here, DPP4 is linked to coronary artery disorder.